{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 58,
  "pageCount": 62,
  "prevPage": 57,
  "nextPage": 59,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a side-by-side comparison structure to explain two distinct but complementary proprietary platforms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/58",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-58",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.62,
        "y": 0.62
      },
      "kind": "list",
      "text": "Robust MOAs in Complex Pathologies; Generate Actionable Drug Candidates; Highly Predictive IND-Enabling Activities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10cd6abf-afd2-4e2f-92f1-80564a82e568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "list",
      "text": "Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database; Proprietary EXPAND technology; Atomized, Novel Binding Scaffold Generation Engine",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2a03c4c-a233-42d5-983b-219785c02e8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.62,
        "y": 0.34
      },
      "kind": "list",
      "text": "1. System-Tissue Biology Model Development; 2. Purpose-Built Physical Biochemistry Engine; 3. Predictive Validation Framework",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1861593-76a4-4fd1-9e03-1ee7e32c91f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94d441ab-e7ad-480d-b3dc-f354a5b7504c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.33,
        "x": 0.08,
        "y": 0.205
      },
      "kind": "title",
      "text": "N-GENIUS PLATFORM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "128d6b14-3018-4f65-9163-04b30c59879f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "N-GENIUS Platform + IMMiXBio™ SMARxT Tissue-Specific™ Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d7d8c82-281b-4997-ac85-fdfdd5fa5b36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.52,
        "y": 0.205
      },
      "kind": "title",
      "text": "TME Normalization™ Technology – SMARxT Tissue-Specific Platform Oncology Application",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7313cad8-5321-4de9-b3b7-4e825edf66b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Canvas framework",
      "slug": "canvas-framework",
      "agent": null,
      "layer": "slide",
      "matchId": "df97a088-5d2b-4d92-874f-2505f69bb549",
      "evidence": "list/bullet: Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database; Proprietary EXPAND technology; Atomized, Novel Binding Scaffold Generation Engine",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 62,
      "from": 35,
      "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}